Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok3. fázis

A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer

A legfontosabb adatok

Ki végzi
Energenesis Biomedical Co., Ltd.
Hol
Columbus, Houston, Jackson, Miami, Palmetto Bay, Salem és Salt Lake City (Egyesült Államok)Mind a 10 helyszín megnézéseMég 1 másik országban, 14 helyszínen
Azonosító
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
230 fő, tervezett
Kezdés
2023. máj. 30.
Tervezett befejezés
2026. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • ENERGI-F703 GEL
  • ENERGI-F703 matched vehicle
A regiszteradat frissítve
2025. október 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with diabetes who have a foot ulcer that has not healed for at least 4 weeks. It tests ENERGI-F703 GEL against a gel without the active drug.

Életkor
18 years and older
Nem
All sexes can join
A betegség stádiuma
The target ulcer must be Wagner Grade 1 to Grade 2, sized 1.5 cm2 to 25 cm2, with no dead tissue (necrosis) or infection.
Korábbi kezelés
People cannot join if they took part in another trial of a new drug within 4 weeks before this study. People who need systemic corticosteroids, drugs that weaken the immune system, or chemotherapy cannot join.
Biomarker vagy leletérték
Diabetes must be diagnosed. This means taking diabetes medicine, or 2 hemoglobin A1c results over 6.5% (48 mmol/mol) and fasting plasma glucose over 126 mg/dL (7 mmol/L), at least 1 week apart.

A részvétel fő kizáró okai

  • Bone infection (osteomyelitis) in the leg or foot, unless treated over 1 year ago with no return
  • Target ulcer shrank by at least 30% during the 2-week standard care period before the study
  • Hemoglobin A1c >12% (108 mmol/mol), serum albumin <2g/dL, prealbumin <10 mg/dL, or liver tests >3 x the upper normal limit
  • HIV, cancer in the last 2 years (some skin or cervix cancers allowed), or ankle brachial index <0.8 or >1.4
  • Pregnant or breastfeeding women; heart attack, bypass or coronary angioplasty within 3 months

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject must be at least 18 years old
  • Subject must have diagnosed with diabetes mellitus (DM), eg, currently under DM medication treatment or subjects with naïve DM with duplicated hemoglobin A1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least 1 week apart before screening
  • Subject must have at least 1 cutaneous ulcer on the foot and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If 2 or more ulcers have the largest size, the one with worst grade will be selected. If 2 or more ulcers have the largest size and grade, the one with longest duration will be selected
  • The target ulcer is classified as Grade 1 to Grade 2 ulcer according to Wagner Grading System and with ulcer size of 1.5 cm2 to 25 cm2
  • Diabetic foot ulcers should be free of any necrosis or infection
  • Subject has signed the written informed consent form
  • Male subjects must be surgically sterile or commit to the use of a reliable method of birth control (must agree to use double-barrier contraception in the event of sexual activity) or be practicing abstinence for the duration of the study and for 30 days after study treatment administration
  • Female subjects are eligible only if all of the following apply:; Not pregnant with a negative serum pregnancy test at Screening visit and negative urine pregnancy test within 24 hours before randomization (test not required for females of non-childbearing potential, defined as surgically sterile [eg, hysterectomy or bilateral oophorectomy] or postmenopausal [amenorrheic for at least 1 year]); Not lactating; Not planning to become pregnant during the study; If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study and at least 30 days after study treatment administration

Ki nem vehet részt

  • Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents
  • With coronary heart disease with myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty within 3 months prior to study (patients who have undergone peripheral angioplasty should be excluded unless the surgery was performed at least 30 days prior to screening)
  • Known or suspected history of drug abuse or a recent history of alcohol abuse (regularly drinks >4 units of alcohol per day: 1 unit = 8 oz. beer, 3 oz. wine, or 1 oz. spirits) within 6 months prior to screening (within 6 months prior to screening includes both drug abuse and alcohol abuse)
  • Enrollment in any investigational drug trial within 4 weeks before entering this study
  • History or evidence of osteomyelitis as confirmed by the investigator. An x-ray/pathology assessment of debridement or a probe-to-bone (PTB) test will be used to determine presence of osteomyelitis. However, participants who have a history or evidence of osteomyelitis in other parts of their body are eligible to participate in the study. If the medical history of osteomyelitis was cured by antibiotic therapy, surgery or amputation for more than 1 year, and no recurrence, no finding to the current leg and foot after testing, the participant can be enrolled
  • With target ulcer size decreased by at least 30% after at least 2 weeks of standard of care-only period between screening and randomization
  • With known or suspected hypersensitivity to any ingredients of study product and vehicle
  • History or positive test results for HIV
  • Malignancy in the last 2 years, with the exception of non-metastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix
  • With any condition judged by the investigator that entering the trial may be detrimental to the subject -
  • With poor nutritional status (serum albumin <2g/dL or prealbumin <10 mg/dL), poor diabetic control (hemoglobin A1c >12%), a leukocyte counts <2,000/mm3, abnormal liver function (aspartate aminotransferase, alanine aminotransferase >3 x upper limit of normal range) within 21 days before Randomization visit
  • Subjects with highly exudated wounds which require dressing changes more than 3 times a day may be enrolled, but heavily exudated wounds should not be selected as target ulcers
  • Ankle brachial index <0.8 or >1.4

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 14 helyszínen

  • IACT HealthColumbus, Egyesült ÁllamokContact: Joseph Surber, Dr.Résztvevőt keres
  • Mt Olympus Medical ResearchHouston, Egyesült ÁllamokContact: Julie Lester, Dr.Résztvevőt keres
  • The Jackson Clinic, PAJackson, Egyesült ÁllamokContact: Kellie Wallace-Wilding, Dr.Résztvevőt keres
  • A and D Doctor CenterMiami, Egyesült ÁllamokContact: Yordan Orive, Dr.Résztvevőt keres
  • Advanced Medical Research InstituteMiami, Egyesült ÁllamokContact: Enrique Pelayo, Dr.Résztvevőt keres
  • Bioclinical ResearchMiami, Egyesült ÁllamokContact: Rogelio Iglesias, Dr.Résztvevőt keres
  • Reliant Medical ResearchMiami, Egyesült ÁllamokContact: Ramses Vega, Dr.Résztvevőt keres
  • New Horizons ResearchPalmetto Bay, Egyesült ÁllamokContact: Derrick H. Diaz, Dr.Résztvevőt keres
  • Salem Veterans Affairs Medical Center VAMCSalem, Egyesült ÁllamokContact: Aliza Lee, Dr.Résztvevőt keres
  • Wasatch Clinical ResearchSalt Lake City, Egyesült ÁllamokContact: Clark Larsen, Dr.Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This Phase 3 study is a randomized, double-blind, vehicle-controlled, multiple-center, parallel study to evaluate efficacy and safety of ENERGI-F703 GEL compared with vehicle control in subjects with Wagner Grade 1 to Grade 2 diabetic foot ulcers. Baseline target ulcer size (<16 cm2 vs ≥16 cm2 ) will be included as a stratification factor. Subjects will be randomized 1:1 to receive ENERGI-F703 GEL or vehicle control using an interactive web response system for randomization to automatically assign a unique subject randomization number. Total duration of the study will be up to 31 weeks including Screening visit (approximately 2 to 3 weeks), double-blind dosing/observation phase (16 weeks), and a safety follow-up of 12 weeks after the last administration of study treatment.

A vizsgálat 2 csoportja

  • ENERGI-F703 GELA vizsgált kezelés

    ENERGI-F703, topical application, 2 times daily for 16 weeks

  • ENERGI-F703 matched vehiclePlacebo, összehasonlításként

    ENERGI-F703 matched vehicle, topical application, 2 times daily for 16 weeks

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase III Study to Evaluate Efficacy and Safety of ENERGI-F703 GEL in Subjects With Diabetic Foot Ulcers
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2025. október 2.